A phase II study of nab-Paclitaxel therapy in reductive dose for patients with advanced/recurrent gastric cancer after prior treatments including fluoropyrimidine.
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2017
At a glance
- Drugs Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 08 Jan 2017 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 28 Jan 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 25 Dec 2014 Planned initiation date changed from 1 Jan 2014 to 4 Apr 2014 as reported by University Hospital Medical Information Network - Japan.